INTRODUCTION
gastrointestinal cancer
RECTAL ADENOCARCINOMA, GASTROINTESTINAL CANCER
Great progress in technique and device development has been made in endoscopic resection of early-stage gastrointestinal cancer with endoscopic mucosal resection and endoscopic submucosal dissection (ESD) (The synthetic self-assembling peptide, TDM-621 (3-D Matrix, Tokyo, Japan), is derived from nonliving sources and consists of 16 amino acid residues. It is usually in the form of an aqueous solution (that easily passes through the catheter) but can form a gel (self-assembling) under specific physiological conditions (neutral pH or an environment in which salts such as NaTDM-621 has noninvasive properties, including safety and operability, and is a safe material that may contribute to hemostasis in the gastrointestinal endoscopic treatment field. However, no clinical studies have fully examined its efficacy and safety in the gastrointestinal field in a multicenter randomized setting. This multicenter, open-label, randomized controlled trial aimed to clarify the efficacy and safety of TDM-621 in achieving hemostasis during ESD in patients with gastric or rectal adenocarcinomas for which ESD is indicated.